Category: Finance
-
Ginkgo Acquires Biomaterials Maker as Industry Consolidates
A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates.
-
Infographic – Digital Health Keeps Clicking in 2022
While venture capital funding for digital health start-ups worldwide is down compared to last year, the pace so far in 2022 remains on an historically strong track.
-
Synthetic Bio Microbiome Biotech Gains $15M in Seed Funds
A developer of therapies produced with synthetic biology for diseases linked to microbes in the gut is raising $15 million in seed financing.
-
Surgical Robotics Company Raises $55M in Early Funds
A developer of robotic systems for cataract and other eye surgeries is raising $55 million in its first venture financing round.
-
Infographic – US Biotech Investments Stay Strong
The first half half of 2022 shows venture investments in U.S. biotechnology start-ups cooled from the blistering pace of last year, but biotech remains a robust sector.
-
NIH Funding Engineered Phage Screening Device
National Institutes of Health is funding initial development of a microfluidic device that tests engineered viruses for their ability to kill disease-causing bacteria.
-
Precision Protein Design Start-Up Gains $40M in Early Funds
A start-up company designing and testing precise proteins within live animals to speed creation of new therapeutics is raising $40 million in its first venture round.
-
Diabetes Cell Therapy Biotech Acquired in $320M Deal
A developer of therapies derived from stem cells to replace malfunctioning islet cells in people with type 1 diabetes was acquired by Vertex Pharmaceuticals.
-
Infographic – Q2 Venture Funds Decline Continues
Venture capital funds for North American technology start-ups continued their fall in the second quarter, with later-stage rounds showing the greatest drop.
-
Precision Microbial Resistance Joint Venture Formed
Biotech, pharma, and diagnostics companies are forming a new business to design precision diagnostics and treatments for drug-resistant microbes.